You guys! Janet Woodcock has not responded to
Post# of 148292
(Total Views: 813)
Posted On: 03/09/2021 8:33:05 PM
You guys!
Janet Woodcock has not responded to my email. Do you think it’s because she’s burning red hot with shame over her lack of action and can’t pull herself together to admit she made a mistake? Did I just shame the head of the FDA into reconsidering an EUA for Leronlimab? I can think of no other possibility. Surely the head of the FDA has time to respond to my scathing email.
Pop quiz!
If a friend of mine follows 18 different companies but only invests in 4, on a day where everything is as green as a leprechaun’s ass, how many of my friend’s four stocks were green today?
I’ll give you the answer. It was 1. One stock was green today and it was by just .07%. I, err, I mean my friend, made $1 on that stock today. What are the odds?
Seriously. Can someone run a probability analysis on whether or not I’m the dumbest investor alive? No? It would break your scientific calculator?
Got it.
OK.
Now to the filet and red wine portion of my post…
When you find yourselves in times of trouble, Nighttime Respert comes to you. Slinging words of wisdom, let it be…
So your stock took a shit, huh?
The market is just staring you straight in the face dog-style while it squeezes every last turd out, eh? Arching its back way more than necessary for the final nugget to drop, scraping over and over at the ground with its paws afterwards before finally breaking eye contact?
Yeah, I’ve had the same experience so far this week.
It’s always hard when you’re taking a bit of an unconventional path to your destination. Cytodyn, a very small company with very big dreams, has been trying to do just that. The product was left for dead. The FDA have been anal retentive bastards along the way. Paths have opened and closed with stunning speed. Break room microwaves have seen extraordinary amounts of fish reheated.
Sometimes you have to get knocked down before you can get back up again. It’s called the Chumbawamba Effect.
But on the subject of getting knocked down, I’m reminded of the great, but relatively unknown American ping pong legend, Barry Badrinath. He was absolutely money with the paddle in his hands. Unstoppable. But one time he got in over his head during a game of ping pong in Ding Dang. Turns out that not everyone is a good loser. He won but got a ping pong paddle shoved up his ass for his efforts. And yes, you’d think it would definitely suck to have the handle of a ping pong paddle shoved up your ass, but it wasn’t the handle. Eventually, his buddy’s great gam gam, a grizzled old woman who had seen and done it all, set him straight when she said that she’s gotten over things and “you will too”.
We’re all Barry Badrinath.
We’re all going to get over this temporary setback. In fact, we’ve all gotten over this exact setback at least four times in recent memory. We drop significantly on disappointing or frustrating news of delay, while the science remains sound, and then we start moving back up again soon after. BECAUSE THE SCIENCE REMAINS SOUND.
Look, I’m with you in that a big pharma company could have likely pulled this over the finish line already. They get their fair share of bad luck and delays as well, but as a whole they are able to get out of the gate faster. They have a larger horse, better stables, nutritionists, and can afford to hire the best trainers, jockeys, and handlers. They can enter the best, largest races. There are no unnecessary obstacles as a result.
Hell, big pharma could get just about anything approved if they really wanted to. Let’s pick Smudging, which is the act of burning sage to ward off negativity. They’d have smudged just three houses with the primary endpoint being “Reduction in Negativity as Recorded on the Capplemen Longitudinal Negativity Index”. But once three patients finished the trial and failed the endpoint they’d just switch it to “Does it Smell Sage-y in Here? And they’d immediately have approval and become a blockbuster.
Don’t fall for it.
We’re on track. Nothing has changed but the end date. You’ll look back and laugh at the times you bought shares over $7 or how every time you thought it was a low and bought you were immediately proven wrong with a much lower low.
It’s fine. You’ll be fine.
Maybe you ARE fine.
Though some of you are for sure Uggos. I mean, I don’t want to be mean, but that’s a statistical fact. Not everyone can be a looker. With over 40,000 investors, the number of ugly people invested in CYDY is for sure statistically significant. As would be the number of attractive people.
Long story short, I feel a Bogle band forming. Might be a Phantom, might be an Essential Red band. But regardless #TechnicalAnalysis says it’s coming. So please remember this:
When the broken hearted people living in the world agree. There will be an answer…
Let it be.
Janet Woodcock has not responded to my email. Do you think it’s because she’s burning red hot with shame over her lack of action and can’t pull herself together to admit she made a mistake? Did I just shame the head of the FDA into reconsidering an EUA for Leronlimab? I can think of no other possibility. Surely the head of the FDA has time to respond to my scathing email.
Pop quiz!
If a friend of mine follows 18 different companies but only invests in 4, on a day where everything is as green as a leprechaun’s ass, how many of my friend’s four stocks were green today?
I’ll give you the answer. It was 1. One stock was green today and it was by just .07%. I, err, I mean my friend, made $1 on that stock today. What are the odds?
Seriously. Can someone run a probability analysis on whether or not I’m the dumbest investor alive? No? It would break your scientific calculator?
Got it.
OK.
Now to the filet and red wine portion of my post…
When you find yourselves in times of trouble, Nighttime Respert comes to you. Slinging words of wisdom, let it be…
So your stock took a shit, huh?
The market is just staring you straight in the face dog-style while it squeezes every last turd out, eh? Arching its back way more than necessary for the final nugget to drop, scraping over and over at the ground with its paws afterwards before finally breaking eye contact?
Yeah, I’ve had the same experience so far this week.
It’s always hard when you’re taking a bit of an unconventional path to your destination. Cytodyn, a very small company with very big dreams, has been trying to do just that. The product was left for dead. The FDA have been anal retentive bastards along the way. Paths have opened and closed with stunning speed. Break room microwaves have seen extraordinary amounts of fish reheated.
Sometimes you have to get knocked down before you can get back up again. It’s called the Chumbawamba Effect.
But on the subject of getting knocked down, I’m reminded of the great, but relatively unknown American ping pong legend, Barry Badrinath. He was absolutely money with the paddle in his hands. Unstoppable. But one time he got in over his head during a game of ping pong in Ding Dang. Turns out that not everyone is a good loser. He won but got a ping pong paddle shoved up his ass for his efforts. And yes, you’d think it would definitely suck to have the handle of a ping pong paddle shoved up your ass, but it wasn’t the handle. Eventually, his buddy’s great gam gam, a grizzled old woman who had seen and done it all, set him straight when she said that she’s gotten over things and “you will too”.
We’re all Barry Badrinath.
We’re all going to get over this temporary setback. In fact, we’ve all gotten over this exact setback at least four times in recent memory. We drop significantly on disappointing or frustrating news of delay, while the science remains sound, and then we start moving back up again soon after. BECAUSE THE SCIENCE REMAINS SOUND.
Look, I’m with you in that a big pharma company could have likely pulled this over the finish line already. They get their fair share of bad luck and delays as well, but as a whole they are able to get out of the gate faster. They have a larger horse, better stables, nutritionists, and can afford to hire the best trainers, jockeys, and handlers. They can enter the best, largest races. There are no unnecessary obstacles as a result.
Hell, big pharma could get just about anything approved if they really wanted to. Let’s pick Smudging, which is the act of burning sage to ward off negativity. They’d have smudged just three houses with the primary endpoint being “Reduction in Negativity as Recorded on the Capplemen Longitudinal Negativity Index”. But once three patients finished the trial and failed the endpoint they’d just switch it to “Does it Smell Sage-y in Here? And they’d immediately have approval and become a blockbuster.
Don’t fall for it.
We’re on track. Nothing has changed but the end date. You’ll look back and laugh at the times you bought shares over $7 or how every time you thought it was a low and bought you were immediately proven wrong with a much lower low.
It’s fine. You’ll be fine.
Maybe you ARE fine.
Though some of you are for sure Uggos. I mean, I don’t want to be mean, but that’s a statistical fact. Not everyone can be a looker. With over 40,000 investors, the number of ugly people invested in CYDY is for sure statistically significant. As would be the number of attractive people.
Long story short, I feel a Bogle band forming. Might be a Phantom, might be an Essential Red band. But regardless #TechnicalAnalysis says it’s coming. So please remember this:
When the broken hearted people living in the world agree. There will be an answer…
Let it be.
(25)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼